Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 997.50
-14.30 (-1.41%)
At close: Jul 30, 2025
FARO Technologies Revenue
In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B INR with 13.91% growth. Cohance Lifesciences had revenue of 4.02B in the quarter ending March 31, 2025, with 58.94% growth.
Revenue
11.98B
Revenue Growth
+13.91%
P/S Ratio
31.29
Revenue / Employee
10.04M
Employees
1,193
Market Cap
374.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 11.98B | 1.46B | 13.91% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | 10.10B | 1.76B | 21.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,729.85B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,429.39B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 631.21B |